Platform: Bioavailability Enhancement

Enhancing the bioavailability of poorly soluble drugs

Is there a promising drug in your pipeline with low bioavailability or a drug in your portfolio that would benefit from a faster therapeutic onset, improved safety as a result of a lower dose, or minimization of food effect? The bioavailability of a drug is influenced by its solubility in the aqueous environment of the gastrointestinal (GI) tract. Extent and rate of solubility are key determinants among several pharmacological and physicochemical properties that influence the rate of onset of action, the inter-patient variability, and food effect .

Aptalis Pharmaceutical Technologies can provide a solution. Our patented, and proprietary Biorise^® technology enables and improves the bioavailability of drugs with low solubility. Biorise has been proven to improve the rate and extent of drug solubilization than can result in faster onset of action, improved bioavailability, equivalent therapy at lower doses, and/or effective oral dosing of poorly soluble drug candidates.